Novus Therapeutics (NVUS) Misses Q3 EPS by $3.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Novus Therapeutics Reports Third Quarter 2020 Financial Results
November 16, 2020 4:00 PM ESTCompany to host conference call and webcast at 4:30pm ET today
IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (Novus) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today reported its financial results for the quarter ended September 30, 2020, and operational highlights.
Recent Business Highlights
Completed the acquisition of Anelixis Therapeutics, Inc., a privately held clinical stage biotechnology company developing a next generation... More